Six IPOs raised $2.3 billion this past week, including the year's largest US offering, China's logistics giant ZTO Express. ZTO priced above the range and proceeded to drop 15% on its first day, highly unusual given its pricing premium, size and...read more
Myovant Sciences, a newly-formed biotech developing an acquired therapy for endocrine disorders, raised $218 million by offering 14.5 million shares at $15, the high end of the range of $12 to $15. Myovant Sciences plans to list on the NYSE under the symbol...read more
Six companies are on the US IPO calendar to raise $2.2 billion in the week ahead, or $2.6 billion including a large SPAC. October is set to surpass September as the...read more
Three IPOs raised $495 million this week, led by iRhythm Technologies (IRTC), which popped 53% on its first day. The other two IPOs, CRISPR Therapeutics (CRSP) and Forterra (FRTA), priced below...read more
US IPO Weekly Recap: BlackLine soars but 5 IPOs struggle including year's largest offering
Six IPOs raised $2.3 billion this past week, including the year's largest US offering, China's logistics giant ZTO Express. ZTO priced above the range and proceeded to drop 15% on its first day, highly unusual given its pricing premium, size and...read more
Ending endocrine disorders: Myovant Sciences prices upsized IPO above the range at $15
Myovant Sciences, a newly-formed biotech developing an acquired therapy for endocrine disorders, raised $218 million by offering 14.5 million shares at $15, the high end of the range of $12 to $15. Myovant Sciences plans to list on the NYSE under the symbol...read more
US IPO Week Ahead: China's ZTO Express delivers largest IPO of 2016 in a 6-deal week
Six companies are on the US IPO calendar to raise $2.2 billion in the week ahead, or $2.6 billion including a large SPAC. October is set to surpass September as the...read more
US IPO Weekly Recap: Two deals flounder while one soars
Three IPOs raised $495 million this week, led by iRhythm Technologies (IRTC), which popped 53% on its first day. The other two IPOs, CRISPR Therapeutics (CRSP) and Forterra (FRTA), priced below...read more